Tanvex BioPharma, Inc. (6541.TW) TAI
Currency In TWD
- General
- Statistics
- Historical Data
- Profile
- Financials
Tanvex BioPharma, Inc.
Address
802 West Bay Road
George Town, KY1-1205
Cayman Islands (the)
Phone
+886 2 2655 8080
Website
Sector
Healthcare
Industry
Biotechnology
Employees
139
First IPO Date
August 13, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Stephen Lam | Chief Executive Officer & Director | 0 | N/A |
| Allen Y. Chao | Founder & Honorary Chairman | 20,000 | 1946 |
| John R. Mosack | Chief Operating Officer of US | 0 | N/A |
| Val Chen | Vice President of Finance, Director of Operations. Management & Corporate Governance Officer | 0 | N/A |
| Angela Luan | Chief Financial Officer & Corporate Governance Officer | 0 | N/A |
| Zheng Xia | Chief Technology Officer | 0 | N/A |
| Miguel Carrion | Vice President of R&D - USA | 0 | N/A |
| Marc Goemans | Chief Commercial Officer | 0 | N/A |
| Linda Grillo | Director of Sales & Marketing | 0 | N/A |
| James Williamson | Chief Accounting Officer | 0 | N/A |
Description
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
